Medicare Enrolled

Dr. Leyka Barbosa, M.D.

Rheumatology · Dallas, TX
Practice pattern: Mixed Practice — Diverse clinical practice across multiple procedure types
Speaking/Promotional
7777 FOREST LANE, Dallas, TX 75230
9725662234
In practice since 2007 (19 years)
NPI: 1427101344 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Barbosa from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Barbosa? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Barbosa

Dr. Leyka Barbosa is a rheumatology specialist in Dallas, TX, with 19 years of NPI registration. Based on federal Medicare data, Dr. Barbosa performed 18,199 Medicare services across 309 unique beneficiaries.

Between the years covered by Open Payments, Dr. Barbosa received a total of $132,616 from 41 pharmaceutical and/or device companies across 857 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in rheumatology. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Barbosa is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 19 years in practice ▲ Top 32% volume in TX $132,616 industry payments

Medicare Practice Summary

Medicare Utilization ↗
18,199
Medicare services
Top 32% in TX for rheumatology
309
Unique beneficiaries
$15
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~958 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

Procedure Volume Avg. paid Avg. submitted
Golimumab infusion (Simponi Aria) 14,850 $11 $59
Denosumab injection (Prolia/Xgeva) 2,340 $18 $40
Office visit, established patient (30-39 min) 481 $97 $325
Injection, ketorolac tromethamine, per 15 mg 149 $0 $35
Administration of chemotherapy into vein, 1 hour or less 122 $105 $500
Infusion, normal saline solution, 250 cc 87 $1 $20
Injection, zoledronic acid, 1 mg 65 $6 $200
Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle 44 $59 $151
Drug injection, under skin or into muscle 18 $11 $50
New patient office visit, complex (60-74 min) 15 $124 $600
Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less 14 $48 $200
Office visit, established patient, complex (40-54 min) 14 $130 $400
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
82.2% high complexity
15.0% medium
2.8% routine

Industry Payment Transparency

Open Payments through 2024 ↗
$132,616
Total received (2018-2024)
Avg $18,945/year across 7 years
Top 6% in TX for rheumatology
41
Companies
857
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$103,878 (78.3%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$19,161 (14.4%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$9,578 (7.2%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$11,887
2023
$17,169
2022
$18,851
2021
$9,715
2020
$12,576
2019
$33,677
2018
$28,741

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
PFIZER INC.
$43,731
AbbVie, Inc.
$29,318
AbbVie Inc.
$15,846
ABBVIE INC.
$15,730
Boehringer Ingelheim Pharmaceuticals, Inc.
$6,635
Amgen Inc.
$4,745
Fresenius Kabi USA, LLC
$3,013
Janssen Biotech, Inc.
$1,628
GlaxoSmithKline, LLC.
$1,432
GENZYME CORPORATION
$1,358
Lilly USA, LLC
$1,351
Genentech USA, Inc.
$1,212
Novartis Pharmaceuticals Corporation
$1,123
AstraZeneca Pharmaceuticals LP
$1,044
Janssen Scientific Affairs, LLC
$857
Mallinckrodt Hospital Products Inc.
$777
UCB, Inc.
$602
Aurinia Pharma U.S., Inc.
$412
Johnson & Johnson Health Care Systems Inc.
$270
Mallinckrodt Enterprises LLC
$231
ANI Pharmaceuticals, Inc.
$192
Stryker Corporation
$125
Radius Health, Inc.
$121
Biogen, Inc.
$110
Octapharma USA, Inc.
$100
E.R. Squibb & Sons, L.L.C.
$99
Gilead Sciences, Inc.
$98
Mallinckrodt LLC
$85
Organon Llc
$69
Horizon Therapeutics plc
$54
MEDAC PHARMA, INC.
$45
Ultragenyx Pharmaceutical Inc.
$34
Alexion Pharmaceuticals, Inc.
$24
Bioventus LLC
$22
Exeltis, USA Inc.
$20
Antares Pharma, Inc.
$20
Organon LLC
$19
Sandoz Inc.
$17
Fidia Pharma USA Inc.
$17
Celltrion USA Inc.
$15
Zimmer Biomet Holdings, Inc.
$15
Top 3 companies account for 67.0% of total payments
Associated products mentioned in payments ›
ACTHAR · AMJEVITA · AVSOLA · Actemra · BENLYSTA · Bimzelx · COSENTYX · CYLTEZO · Cimzia · Crysvita · Durolane · Enbrel · GPS III PLATELET CONCENTRATION SYSTEM · HADLIMA · HUMIRA · HYMOVIS · HYRIMOZ · Humira · IDACIO · ILARIS · INFLECTRA · KEVZARA · KRYSTEXXA · LUPKYNIS · MAKO · OCTAGAM IMMUNE GLOBULIN (HUMAN) · OFEV · ORENCIA · Otezla · Otrexup · PURIFIED CORTROPHIN GEL · Prolia · REMICADE · RENFLEXIS · REYVOW · RHEUMATOID ARTHRITIS DISEASE · RINVOQ · Rasuvo · Rinvoq · Rituxan · SAPHNELO · SIMPONI · SIMPONI ARIA · SKYRIZI · STELARA · TALTZ · TAVNEOS · TOFIDENCE · TREMFYA · Tavneos · Tyenne · Tymlos · XELJANZ · YUFLYMA
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

The majority of payments (78%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in rheumatology and does not inherently indicate bias, but patients may wish to be aware. Total industry engagement is in the top 6% for rheumatology in TX.

Equivalent to $729 per 100 Medicare services performed
Looking for a rheumatology specialist in Dallas?
Compare rheumatologists in the Dallas area by procedure volume, costs, and industry payment transparency.
Browse rheumatologists nearby

Geographic Context

Rheumatologists within 10 mi
98
Per 100K population
3.8
County median income
$74,149
Nearest hospital
MEDICAL CITY DALLAS HOSPITAL
0.0 mi

Data Sources

Provider Registry NPPES Weekly updates
Medicare Enrollment PECOS Monthly updates
Practice Data Medicare Util. Annual (CY lag)
Industry Payments Open Payments CY 2024
Disciplinary History — Not public N/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →

Summary

Dr. Barbosa is a mixed practice specialist, with moderate Medicare volume, with speaking/promotional industry engagement in the top 6% of TX peers, with 19 years of NPI registration.

This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →

Frequently Asked Questions

Is Dr. Barbosa experienced with golimumab infusion (simponi aria)?
Based on Medicare claims data, Dr. Barbosa performed 14,850 golimumab infusion (simponi aria) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Barbosa receive payments from pharmaceutical companies?
Yes. Dr. Barbosa received a total of $132,616 from 41 companies across 857 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Barbosa's costs compare to other rheumatologists in Dallas?
Dr. Barbosa's average Medicare payment per service is $15. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Barbosa) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →